PDLIinactive

PDL BIOPHARMA, INC.

Healthcare·Neurology·Phase 3
Neurology

PDL BIOPHARMA, INC. (PDLI): 2 pipeline candidates. Updated within the last hour.

7.7/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health10.0

0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for PDL BIOPHARMA, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$126.8M

Quarterly Burn

—

Runway

—

Revenue

—

Pipeline (2 candidates)

DrugPhase
amphoraPhase 2
solanezumabPhase 3
·CEO: Southwood Boulevard Incline

Frequently asked questions

How many drug candidates are in PDL BIOPHARMA, INC.'s pipeline?

PDL BIOPHARMA, INC. (PDLI) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is PDL BIOPHARMA, INC.'s lead drug candidate?

PDL BIOPHARMA, INC.'s most advanced tracked candidate is amphora (Phase 2) for Prevention of chlamydia and gonorrhea.

Who is the CEO of PDL BIOPHARMA, INC.?

Southwood Boulevard Incline is the chief executive officer of PDL BIOPHARMA, INC. (PDLI).

Get the full picture on PDL BIOPHARMA, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar